Samsung Medical Center | GenomeWeb

Samsung Medical Center

A Pfizer research group, working with Seoul's Samsung Medical Center, has published a study demonstrating a multiplex method for detecting ALK, ROS1, and RET fusions in a single assay.

Using NanoString's nCounter technology, researchers from Pfizer and Seoul National University have developed an ALK test they hope will be as accurate as the gold standard fluorescence in situ hybridization test for identifying patients who could benefit from Pfizer's Xa

NEW YORK (GenomeWeb News) – Agilent Technologies separately announced on Thursday a collaboration with Samsung Medical Center and the creation of a new center for neurometabolomics in South Korea.

The deal also takes Seegene into the personalized medicine space. In addition to tests for detecting cancer, the two companies will develop tests to determine how patients respond to cancer therapies.

Seegene will contribute its DPO and READ PCR technologies; while SMC will provide clinical and disease pathology expertise and the first test sites for the new assays.

Under the terms of the partnership, Samsung will provide samples from Korean patients. Pfizer, in turn, will conduct genomic profiling on the samples and analyze the data in order to link gene signatures to patient outcomes.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.